Illumina Buys Helixis for Up to $105M; Unveils Sub-$15K Benchtop PCR Platform | GenomeWeb

This article was originally published on July 27.

By Ben Butkus

Illumina said today that it has acquired privately held real-time PCR and nucleic acid-analysis firm Helixis in a deal that could be worth as much as $105 million.

Concurrent to the announcement, Illumina unveiled a new benchtop PCR instrument developed by Helixis, called the Eco real-time PCR system, that it said will cost about a quarter the price of existing PCR systems while delivering the same level of performance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.